Results 11 to 20 of about 2,984 (199)

Impact of CMV-specific immune reconstitution at the end of letermovir prophylaxis on the development of late cytomegalovirus infection in haematopoietic stem cell transplant recipients (INMUNOEND): a protocol for a prospective, observational, multicentre study. [PDF]

BMJ Open
Introduction: Cytomegalovirus (CMV) infection is a common complication in patients undergoing haematopoietic stem cell transplantation (SCT). Letermovir (LTV) prophylaxis during the first 100 days post-SCT is effective and safe in preventing this ...
Castón JJ, Aparicio C, Paez-Vega A, Pozo López L, García E, Martín C, Ruiz-Arabi E, Cuesta-Casas MÁ, Bermúdez-Rodriguez MA, Cerezo-Martín JM, González-Sierra PA, Machuca I, Martín Domínguez FM, Saldaña-Moreno R, Herrera C, Torre-Cisneros J.   +15 more
europepmc   +3 more sources

Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR-T Cell Recipients-PART 2: Antiviral Therapy and Virus-Specific T Cell Therapy for HCMV in Allo-HSCT. [PDF]

Rev Med Virol
ABSTRACT Human cytomegalovirus (HCMV) reactivation is a common and significant complication after allogeneic haematopoietic stem cell transplantation (allo‐HSCT), causing potentially life‐threatening disease. Antiviral therapy approaches for HCMV are often limited by toxicities and the risk of developing antiviral drug resistance.
Sutrave G, Yong MK, Kaplan D, Gottlieb DJ, Abendroth A, Slobedman B, Blyth E, Stern L.   +7 more
europepmc   +2 more sources

POSSIBILITIES OF PREVENTION AND TREATMENT OF HUMAN CYTOMEGALOVIRUS INFECTIONS INCLUDING NEW DRUGS AND COMPOUNDS WITH POTENTIAL APPLICATION [PDF]

Postępy Mikrobiologii, 2019
Anna Majewska, Beata Młynarczyk-Bonikowska, Magdalena Malejczyk, Sławomir Majewski, Grażyna Młynarczyk   +4 more
doaj   +4 more sources

Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR T Cell Recipients - PART 1: Risk Factors, Clinical Impact and Immune Response. [PDF]

Rev Med Virol
ABSTRACT Human cytomegalovirus (HCMV) is one of the most important opportunistic pathogens in immunocompromised individuals, including allogeneic haematopoietic stem cell transplant (allo‐HSCT) recipients. In allo‐HSCT, HCMV seropositivity of the recipient and donor is associated with inferior survival outcomes, and post‐transplant HCMV reactivation is
Kaplan D, Blyth E, Sutrave G, Yong MK, Gottlieb DJ, Abendroth A, Slobedman B, Stern L.   +7 more
europepmc   +2 more sources

Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients

Drug Design, Development and Therapy
Raymund R Razonable1,2 1Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, MN, USA; 2William J von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USACorrespondence ...
Raymund R Razonable
exaly   +2 more sources

Letermovir use to treat complex cytomegalovirus reactivations in two heart transplant recipients

Antiviral Therapy, 2022
Letermovir, an anti-cytomegalovirus (CMV) drug, is recommended as a prophylactic agent in patients at risk of CMV infection/reactivation after allogeneic hematopoietic stem cell transplant.
Aude Boignard, Caroline Augier, Mathilde Kheng, Olivier Epaulard, Raphaele Germi   +4 more
doaj   +1 more source

Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation under 100-Day Letermovir Prophylaxis: A Real-World 1-Year Follow-Up Study

Viruses, 2023
The prevention and management of cytomegalovirus (CMV) reactivation is important to improve the outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) recipients.
Dukhee Nho, Raeseok Lee, Sung-Yeon Cho, Dong-Gun Lee, Eun-Jin Kim, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Yoo-Jin Kim, Seok Lee, Hee-Je Kim   +10 more
doaj   +1 more source

Real-World Evaluation of Letermovir Use in Kidney Transplant Recipients: Drug Interactions, Safety, and Impact on Renal Function [PDF]

Transplant International
Ilies Benotmane, Ilies Benotmane, Betoul Schvartz, Cyril Garrouste, Florence Runyo, Charlotte Boud’hors, Charlotte Boud’hors, Gauthier Flahaut, Clément Danthu, Dominique Bertrand, Sophie Caillard, Sophie Caillard   +11 more
doaj   +2 more sources

Developing a mechanistic understanding of the nonlinear pharmacokinetics of letermovir and prospective drug interaction with everolimus using physiological‐based pharmacokinetic modeling

Clinical and Translational Science, 2023
Letermovir is approved for use in cytomegalovirus‐seropositive hematopoietic stem cell transplant recipients and is investigated in other transplant settings.
Karsten Menzel, Yuhsin Kuo, Dapeng Chen, Georgy Hartmann, Ying‐Hong Wang, Carolyn R. Cho, Jacqueline B. McCrea, Kazuhiko Asari   +7 more
doaj   +1 more source

Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study

Vaccines, 2021
Background: Real-life data on the administration of letermovir as cytomegalovirus (CMV) primary prophylaxis after allogeneic hematopoietic cell transplantation (HCT) remain limited. Methods: We conducted a retrospective single-center matched cohort study,
Léna Royston, Eva Royston, Stavroula Masouridi-Levrat, Nathalie Vernaz, Yves Chalandon, Christian Van Delden, Dionysios Neofytos   +6 more
doaj   +1 more source